Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa | Synapse
March 3, 2026
Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
Key Points
Virological efficacy is comparable between the long-acting injectable regimen and daily oral therapy.
Participants aged 12 to <20 years were enrolled over 96 weeks to assess various outcomes.
Randomised, open-label trial design assesses acceptability and quality-of-life along with safety metrics.
Potential implications for HIV treatment strategies in adolescents, emphasizing the need for external validation.